Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease
- 7 December 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (24) , 16801-16817
Abstract
Inhibition of leucine-rich repeat kinase 2 (LRRK2) kinase activity represents a genetically supported, chemically tractable, and potentially disease-modifying mechanism to treat Parkinson's disease. Herein, we describe the optimization of a novel series of potent, selective, central nervous system (CNS)-penetrant 1-heteroaryl-1H-indazole type I (ATP competitive) LRRK2 inhibitors. Type I ATP-competitive kinase physicochemical properties were integrated with CNS drug-like properties through a combination of structure-based drug design and parallel medicinal chemistry enabled by sp3-sp2 cross-coupling technologies. This resulted in the discovery of a unique sp3-rich spirocarbonitrile motif that imparted extraordinary potency, pharmacokinetics, and favorable CNS drug-like properties. The lead compound, 25, demonstrated exceptional on-target potency in human peripheral blood mononuclear cells, excellent off-target kinase selectivity, and good brain exposure in rat, culminating in a low projected human dose and a pre-clinical safety profile that warranted advancement toward pre-clinical candidate enabling studies.Keywords
Funding Information
- Merck Sharp and Dohme United Kingdom
This publication has 68 references indexed in Scilit:
- Species differences in drug transporters and implications for translating preclinical findings to humansExpert Opinion on Drug Metabolism & Toxicology, 2012
- Replacing Conventional Carbon Nucleophiles with Electrophiles: Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and ChloridesJournal of the American Chemical Society, 2012
- Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease ModelsACS Chemical Neuroscience, 2012
- Analysis of Kinase Inhibitor Selectivity using a Thermodynamics-Based Partition IndexJournal of Medicinal Chemistry, 2010
- Genome-wide association study reveals genetic risk underlying Parkinson's diseaseNature Genetics, 2009
- A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent BindingDrug Metabolism and Disposition, 2009
- Hydrogen Bonding, Electrostatic Potential, and Molecular DesignJournal of Chemical Information and Modeling, 2009
- Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control studyThe Lancet Neurology, 2008
- Parkinson's disease: clinical features and diagnosisJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's DiseaseNeuron, 2004